ライフサイエンスコーパス: France

1 l Genetics at La Timone Hospital (Marseille, France).

2 with the Moulin-Quignon and la Noira sites (France).

3 technology (Stilla Technologies, Villejuif, France).

4 och (JFJ; Switzerland) and Pic du Midi (PDM; France).

5 tion period (Les Cottes and Grotte du Renne, France).

6 zerland, p=0.23 for Germany, and p=0.037 for France).

7 (VP250; n = 25; DBV Technologies, Montrouge, France).

8 FibroScan 502 Touch device (Echosens, Paris, France).

9 e forest ecosystem of Montiers (Northeastern France).

10 ountries (England, Switzerland, Germany, and France).

11 selected from a German longitudinal cohort (FRANCES).

12 patients in intensive care with COVID-19 in France.

13 the lowest in the populations from southern France.

14 tralia, and 2 from Necker Hospital in Paris, France.

15 at two Middle Paleolithic sites in southwest France.

16 simulation model of the COVID-19 epidemic in France.

17 e regions of Australia, along with Bordeaux, France.

18 conducted in the 47 CF reference centers in France.

19 of men who have sex with men (MSM) living in France.

20 ards and microbiology departments throughout France.

21 to vancomycin was first reported in 1986 in France.

22 ocess is complex and currently unrealized in France.

23 needed to fully assess the pollen season in France.

24 e chest syndrome in four referral centers in France.

25 tatic A-NET diagnosed after January, 2010 in France.

26 e Trends cannot predict the pollen season in France.

27 s at 12 clinical sites in the USA and one in France.

28 13- and 5-year GTs were used in France.

29 rs to non-invasive and invasive infection in France.

30 al biogeochemical reactions in an aquifer in France.

31 important role for non-poultry reservoirs in France.

32 hospitals and health centres in the USA and France.

33 e healthcare use related to this disorder in France.

34 t of 218 watercourses distributed throughout France.

35 n HIV-infected and HIV-negative MSM in Lyon, France.

36 focusing on the United Kingdom, Germany, and France.

37 ur wild Culex pipiens mosquitoes captured in France.

38 p in 2 departments of ophthalmology in Lyon, France.

39 tzerland, South Korea, Singapore, Spain, and France.

40 ing TAVR technology at a nationwide level in France.

41 eshwater food web from the urban Orge River, France.

42 dborne infection and a notifiable disease in France.

43 icated with myocarditis imported in Mainland France.

44 University Hospital of Rennes, France.

45 elop a modified cardiac allocation system in France.

46 to the colder climate in Britain compared to France.

47 ampled periodically over 12 years in western France.

48 for PAR, with or without concomitant AA, in France.

49 ied names, we can detect academic couples in France.

50 Fifteen university and nonuniversity ICUs in France.

51 ence Longitudinal Patient Database panels in France.

52 lar trends were observed for US youth and in France.

53 ct of expert review of lymphoma diagnosis in France.

54 cardiac intensive care units in metropolitan France.

55 -based case-control studies from Denmark and France.

56 +/- 7.1 years) diagnosed with RP, living in France.

57 nd isolation most common in respondents from France.

58 s were mainly driven by data from Poland and France.

59 infections in England, the Netherlands, and France.

60 and treatment of this disease, especially in France.

61 VR versus redo SAVR at a nationwide level in France.

62 ter, observational study that perform EVT in France.

63 re department of two university hospitals in France.

64 uring the early modern period in England and France.

65 n patients with nAMD in clinical practice in France.

66 the rocky seashore off the northern coast of France.

67 in charge of the organ allocation system in France.

68 l weeds in two European countries, Spain and France.

69 for south-western Germany and north-eastern France.

70 Subtype C predominated among MSM living in France.

71 idence observed in the general population in France (0.3%).

72 v. from the Carboniferous of Montagne Noire, France [13], revealed through micro computed tomography

73 mpared with 8.2% and 10.1%, respectively, in FRANCE 2 (p < 0.001 for both).

74 nts from FRANCE TAVI and 4,165 patients from FRANCE 2 were included in this analysis.

75 ulture infective dose (TCID(50)) of D/bovine/France/5920/2014 (D/OK-like).

76 SARS-CoV-2 was detected in 5 individuals in France, 6 in England (including the index case), and 1 i

77 11 tons/capita toward levels in the U.K. and France, ~8 tons/capita, would enable the emissions cut t

78 netic testing for melanoma-prone mutation in France, a country with low to moderate incidence of mela

79 In France, a frequent pattern of coinfection of C. briggsae

80 Among critically ill elderly patients in France, a program to promote systematic ICU admission in

81 tem (Visionix-Luneau Technologies, Chartres, France) after a complete eye exam.

82 nd that it was then invading Europe also, as France already had 12 cases, Germany 16, the UK 9, Italy

83 86,829 in the real-life monitoring group) in France and $11,965 ($93,795 vs. $81,829) in the United S

84 The ICER was $1,754 per LYG in France and $32,415 per LYG in the United States.

85 tion according to a prespecified protocol in France and Belgium, where preimplantation biopsy finding

86 Twenty-nine ICUs in France and Belgium.

87 d countries (USA, UK, Germany, Japan, Italy, France and Canada) were the most prolific during the fir

88 he rule of 3 to recommend genetic testing in France and countries with low to moderate incidence of m

89 2007, BT affected more than 35,000 farms in France and Germany alone.

90 presentative samples from the United States, France and Germany, and in a study testing attitudes abo

91 by different water chlorination processes in France and Germany, resulting in different ClxBPA exposu

92 ype D4.2 MeVs were isolated predominantly in France and Great Britain, countries with higher vaccine

93 transplant recipients from three centers in France and one in Canada who presented with a diagnosis

94 At the same time, studies from France and Sardinia suggested that the genetic prevalenc

95 contemporary with the SARS-CoV-2 pandemic in France and Switzerland, we retrospectively collected cli

96 e achievements of 2 public health targets in France and the early initiation of cART were accompanied

97 as Seoul virus isolates, recently emerged in France and the United Kingdom.

98 calities in China, South Korea, Italy, Iran, France and the United States.

99 went bariatric surgery at a single center in France and were followed for 5 years.

100 l flow immunoassay (LFA; NG Biotech, Guipry, France) and (ii) the EDTA-colistin broth disk elution (E

101 d collected from the Bay of Biscay (Southern France) and 4 of these 42 pharmaceuticals were detected

102 The mineral was observed in Bidart (France) and Gubbio (Italy), suggesting a widespread phen

103 gentamicin-resistant Pseudomonas aeruginosa (France) and methicillin-resistant Staphylococcus aureus

104 ts was greatest in Western Europe (Spain and France) and North America (United States) (up to 39 dist

105 reprocessing facilities located in La Hague (France) and Sellafield (Great Britain).

106 tzerland, p=0.52 for Germany, and p=0.40 for France), and for all assessed countries except France us

107 asound examination, CAP-TE 502 (by Echosens, France), and glucose hydrogen breath test (GHBT) using p

108 ore than male life expectancy, and in Chile, France, and Greece where the two sexes will see similar

109 from 21 sites in Austria, Britain, Germany, France, and Spain for Y. pestis DNA and reconstructed ei

110 -30-20, for the countries of Italy, Germany, France, and Spain.

111 pitals in England, Scotland, Wales, Germany, France, and Sweden.

112 = 102) stool specimens from The Netherlands, France, and Switzerland were tested on the cobas Cdiff a

113 uth Korea, Italy, Spain, Brazil, Germany and France, and the numerical results showed that the framew

114 tion favoring the same alleles in Australia, France, and the United Kingdom.

115 graphical areas such as Austria, Finland and France, and therefore their suitability for AIT and clin

116 ynamics of maternal and paternal lineages in France as well as of autosomal genotypes.

117 The setting was 2 university hospitals in France (at Bordeaux and Dijon) from January 2011 (first

118 onal genomic-medicine initiatives in the UK, France, Australia, and US and provide a roadmap for shar

119 was done in 159 academic centres in Germany, France, Australia, Austria, and the UK.

120 ) to compare the terms related to allergy in France, (b) to assess seasonal variations across the cou

121 c of La Voulte-sur-Rhone Fossil-Lagerstatte, France, bearing eyes with hexagonal and square facets, o

122 d all adult patients operated on with AGB in France between 2007 and 2013.

123 rticle is to describe the episiotomy rate in France between 2013 and 2017 and the factors associated

124 treated with a TAVR device commercialized in France between 2014 and 2018.

125 ho experienced a virological failure (VF) in France between 2015 and 2018, 121 (22.5%) were infected

126 is was a cross-sectional study in 21 ICUs in France between April 20, 2020, and May 21, 2020.

127 sent to 26 hospital radiology departments in France between March 2, 2020, and April 24, 2020.

128 n 6 urban academic level-I trauma centers in France between March 2015 and March 2018.

129 y of the University Hospital of Montpellier (France), between 1997 and 2017 for a suspicion of drug h

130 cities of Dijon, Bordeaux, and Montpellier, France, between March 1999 and March 2001.

131 Leprosy Missions, Fondation Raoul Follereau France, Buruli ulcer Groningen Foundation, Sanofi-Pasteu

132 assessed vaccine impact from 2001 to 2016 in France by estimating the contribution of regional VC dif

133 the University in Toulouse (France), Paris (France), Clermont-Ferrand (France), Liege (Belgium), and

134 2), Giessen (Germany; cohort 3), and Paris (France; cohort 4).

135 ce of Etest MEV (bioMerieux, Marcy l'Etoile, France) compared to that of broth microdilution for 629

136 ithic (Gravettian) karstic Grotte de Cussac (France) contains two areas of human remains in the conte

137 In France, CRS/HIPEC is a safe procedure with an acceptable

138 tered in the Universal Mutation Database-DMD France database.

139 ations in southern Germany and north-eastern France, dating between 300 and 2015 CE, and succeeded in

140 In France, despite a reduction in episiotomy use over the l

141 Field experiments were performed at Auch (France) during two seasons (2010 and 2011).

142 ass windows of the Sainte-Chapelle in Paris, France, during its restoration.

143 (Bizerte, Tunisia) and European (Marseille, France) edges of the Western Mediterranean basin is pres

144 ountries, such as Italy, Spain, Netherlands, France, England and Belgium.

145 conducted at 4 sites in 4 countries (Canada, France, England, and the Netherlands) from which data we

146 ardiac or respiratory disease) at 30 ICUs in France; follow-up was until April 2018.

147 tory events from Italy, Austria, Germany and France followed by local amplification in, and later als

148 ian (COx) clay rock, a formation selected in France for possible radioactive waste disposal.

149 c data both revealed demographic patterns in France for the Neolithic and Bronze Age transitions cons

150 atients, collected from 28 centers mainly in France from 2000 and 2014.

151 ominal surgery at 20 university hospitals in France from February 2016 to July 2018; final follow-up

152 ional study performed at multiple centers in France from May 2014 through November 2018 (the Base Cli

153 men) were recruited from hospitals in Paris, France, from 2014 through 2016.

154 gdom (EMBRACE), the Netherlands (HEBON), and France (GENEPSO).

155 ing, we assessed general public attention in France, Germany and the United Kingdom toward climate ch

156 , Croatia, Czech Republic, Denmark, Estonia, France, Germany, Greece, Italy, Israel, Luxembourg, Pola

157 ase 3 trial in 31 transplantation centres in France, Germany, Hungary, Italy, and Poland.

158 European countries (Belgium, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Poland, Sp

159 countries (Belgium, Canada, Czech Republic, France, Germany, Hungary, Japan, the Netherlands, South

160 ountries (Australia, Canada, Czech Republic, France, Germany, Hungary, Poland, Spain, and the USA), e

161 tres across 15 countries (Australia, Canada, France, Germany, Ireland, Israel, Italy, Japan, New Zeal

162 ight European countries: the United Kingdom, France, Germany, Ireland, Spain, Italy, Denmark and the

163 tres across 11 countries (Australia, Canada, France, Germany, Israel, Italy, Japan, New Zealand, Norw

164 14 countries worldwide (Australia, Belgium, France, Germany, Israel, Italy, New Zealand, Portugal, S

165 pitals located in Australia, Brazil, Canada, France, Germany, Israel, Italy, South Korea, Sweden, the

166 0 hospitals or clinics in Australia, Canada, France, Germany, Israel, Italy, Spain, and the UK, to as

167 gibility from 52 clinical centres in Canada, France, Germany, Israel, Italy, Spain, the UK, and the U

168 , Austria, Belgium, Canada, Chile, Colombia, France, Germany, Israel, Netherlands, New Zealand, Norwa

169 across Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Norway, Spain, and the US

170 secondary care centres in Denmark, Estonia, France, Germany, Italy, Latvia, Lithuania, Romania, Sout

171 (13 countries; Australia, Argentina, Canada, France, Germany, Italy, Mexico, Russia, South Africa, So

172 ntries (Australia, Austria, Canada, Denmark, France, Germany, Italy, Poland, Russia, the Netherlands,

173 s eight countries (the USA, Canada, Belgium, France, Germany, Italy, Spain, and Israel).

174 ates (US) and European Union 5 ([EU5]; i.e., France, Germany, Italy, Spain, and the United Kingdom) d

175 e to severe IBS-C in six European countries (France, Germany, Italy, Spain, Sweden and the UK).

176 s and clinics in Australia, Belgium, Canada, France, Germany, Italy, Taiwan, the USA, and the UK into

177 ACT 1 was done in Australia, Brazil, Canada, France, Germany, Italy, the Netherlands, Peru, Poland, R

178 lgium, the Czech Republic, Denmark, Finland, France, Germany, Italy, the Netherlands, Poland, Spain,

179 s done internationally at eight hospitals in France, Germany, Italy, the UK, and the USA (60 week fol

180 at 17 sites across nine countries (Belgium, France, Germany, Poland, Netherlands, South Korea, Spain

181 pecialty centres in Austria, Czech Republic, France, Germany, Poland, Slovakia, and Switzerland.

182 f the most common European hantaviruses from France, Germany, Slovenia and Finland, such as Puumala v

183 ulgaria, Croatia, Georgia, Hungary, Ukraine, France, Germany, South Africa, the UK, and the USA).

184 centres, hospitals, and clinics in the USA, France, Germany, Spain, and the UK.

185 he USA, Australia, Belgium, Canada, Denmark, France, Germany, Sweden, and the UK).

186 pulations now in Canada, Switzerland, Italy, France, Greece, and Hungary.

187 ohorts from 12 countries (Australia, Brazil, France, Greece, Hong Kong, Italy, Japan, Singapore, Spai

188 s (with participants from Australia, Canada, France, Greece, Italy, the Netherlands, Serbia, Spain, S

189 f six existing longitudinal birth cohorts in France, Greece, Lithuania, Norway, Spain, and the UK of

190 x existing population-based birth cohorts in France, Greece, Lithuania, Norway, Spain, and the United

191 uctions can be expected for coastal areas of France, Greece, Spain and northern Africa.

192 udies of HIV-positive individuals in Europe (France, Greece, the Netherlands, Spain, Switzerland, and

193 France has been heavily affected by the severe acute res

194 landscape, but the territory of present-day France has yet to be connected to the broader European p

195 hospitals in six European countries (Italy, France, Holland, Germany, the UK, and Spain).

196 s accidental introduction into South-Western France in 2004, V. velutina has spread to much of wester

197 er circulatory death (cDCD) was initiated in France in 2015 under a protocol based on the use of norm

198 a closely related BTV-8 strain re-emerged in France in 2015, triggering a second outbreak that is sti

199 To assess how atypical HUS epidemiology in France in the eculizumab era evolved, we undertook a pop

200 etinal implant (PRIMA; Pixium Vision, Paris, France) in which pixels convert images projected from vi

201 in some EU member states, including Finland, France, Ireland, and Italy, with recent losses detected

202 eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA).

203 ure also increases during this age period in France irrespective of age at transplantation.

204 uggests that the decrease in episiotomies in France is an overall tendency which is probably related

205 The cardiac allocation system in France is currently based on urgency and geography.

206 tric oncology centers in the United Kingdom, France, Italy, and the Netherlands, who were enrolled in

207 lation and expansion study at eight sites in France, Italy, and the Netherlands.

208 was done in 19 European academic centres in France, Italy, Greece, the Netherlands, and the UK, and

209 s, or university medical centres) in Canada, France, Italy, the Netherlands, and the UK.

210 ople aged 65-79 y from 5 European countries (France, Italy, the Netherlands, Poland, and the United K

211 ted from 28 hospitals in ten countries (USA, France, Italy, UK, Spain, the Netherlands, Denmark, Isra

212 mmercially available Etest((R)) (Biomerieux, France) kit.

213 (France), Paris (France), Clermont-Ferrand (France), Liege (Belgium), and Monza (Italy).

214 Traub and Frances M.

215 cattle representative of animals raised for France meat production.

216 nducted in 8 comprehensive stroke centers in France (October 2015-October 2016).

217 -wedge cluster randomized trial in 15 EDs in France of 503 patients 75 years and older with a diagnos

218 were 22,270 brain-dead patients diagnosed in France, of whom 161 with extracorporeal membrane oxygena

219 80-year-old tourist from China, who died in France on the 15(th) February.

220 f 243 individuals sampled across present-day France over a period spanning 7,000 y, complemented with

221 nnay grapevines in the Languedoc-Roussillon (France) over two years.

222 ts for 28 wheat genotypes in 16 locations in France, over 16 years of historical weather records.

223 tin for participants in Italy (P = 0.04) and France (P = 0.04) and on soluble transferrin receptor (s

224 iameter varied from 59 (US) to 69 mm (Nancy, France) (p < 0.001), 25.3% of patients having a diameter

225 ts affiliated to the University in Toulouse (France), Paris (France), Clermont-Ferrand (France), Lieg

226 also to detect gastrointestinal syndrome in France (Pearson correlation of 0.66).

227 ients with stage III CC included in the IDEA France phase III study (ClinicalTrials.gov identifier: N

228 ov., from Early Cenomanian La Buzinie amber (France), preserved with its marsupial pouch and content.

229 orts from the USA (Framingham, Mayo Clinic), France (QUALYOR, STRAMBO, OFELY), Switzerland (GERICO),

230 INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hepatites).

231 In late 2011, experts in France recommended the use of highly individualized comp

232 coastal, and remote regions of Europe (Lyon, France, Rogoznica, Croatia, and Pallas, Finland, respect

233 ee) plots at six sites: Denmark (two sites), France, Russia, Sweden and the United Kingdom.

234 s 12 countries in the CALGB/SWOG 80702, IDEA France, SCOT, ACHIEVE, TOSCA, and HORG trials, who start

235 ersitaire Mediterranee Infection, Marseille, France, September 2018 - April 2020, enrolling 7,716 blo

236 iple derived strains in central and southern France, Spain, and southern Germany.

237 d from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium.

238 nia, including MUP specimens from South-West France (SWF) and Moravia, using 3D geometric morphometri

239 4 health centres in the UK, the USA, Israel, France, Switzerland, and South Korea.

240 mL gadoteric acid, Dotarem; Guerbet, Roissy, France) T1-weighted fat-saturated (400/20; section thick

241 mL gadoteric acid, Dotarem; Guerbet, Roissy, France) T1-weighted fat-saturated (400/20; section thick

242 mL gadoteric acid, Dotarem; Guerbet, Roissy, France) T1-weighted fat-saturated (400/20; section thick

243 FRANCE TAVI (French Transcatheter Aortic Valve Implantat

244 om the national prospective French registry (FRANCE TAVI [French Transcatheter Aortic Valve Implantat

245 A total of 12,804 patients from FRANCE TAVI and 4,165 patients from FRANCE 2 were includ

246 y rates were 4.4% and 5.4%, respectively, in FRANCE TAVI compared with 8.2% and 10.1%, respectively,

247 The FRANCE TAVI registry provided reassuring data regarding

248 More than 80% of patients in FRANCE TAVI underwent transfemoral TAVR.

249 Valve Bioprostheses Established by Catheter [FRANCE TAVI]; NCT01777828).

250 From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valv

251 anaidaceans from the Cretaceous of Spain and France that provide conclusive evidence for marsupial ca

252 nd the world, such as the United Kingdom and France, that better balance the interests of insurers an

253 ated by NG-Test Carba 5 (NG Biotech, Guipry, France), the Xpert Carba-R assay (Cepheid, Inc., Sunnyva

254 millennium calibrated years BC in northwest France, the Mediterranean, and the Atlantic coast of Ibe

255 In France, the need for continuous monitoring of transplant

256 5 European countries (Belgium, Switzerland, France, the Netherlands and the United Kingdom) and esti

257 , with the United Kingdom, Ireland, Germany, France, the Netherlands, and Denmark as most affected co

258 st 2017 in 63 hospitals in Belgium, Denmark, France, the Netherlands, and the United States, and foll

259 gistry of CrossBoss and Hybrid Procedures in France, the Netherlands, Belgium and United Kingdom) aim

260 gistry of CrossBoss and Hybrid Procedures in France, the Netherlands, Belgium and United Kingdom, REC

261 lation-based studies conducted in Australia, France, the Netherlands, Slovakia, and the UK were poole

262 parts in five academic hospitals in the USA, France, the UK, and the Netherlands.

263 e 2 trial done at 38 clinics or hospitals in France, the UK, Australia, Canada, Poland, Italy, Ukrain

264 imilar kidneys that had been transplanted in France; these discarded kidneys would be expected to hav

265 famous water frogs (Pelophylax) in southern France, through a fine-scale genetic survey.

266 f colorectal cancer (CRC) stool samples from France to discover CRC specific metagenomic biomarkers.

267 Here we extrapolate from the situation in France to quantify the potential invasion of V. velutina

268 unning from Sweden down to Portugal and from France to Slovenia.

269 The recent fieldwork at Les Cottes (France) transitional site offers a good opportunity to d

270 e armies of the United Kingdom, Germany, and France undertook important work on the transmission of t

271 Results from case control studies from France, United Kingdom, United States, and Australia wer

272 ented the most common bariatric procedure in France until 2010.

273 ance), and for all assessed countries except France using ASCO-VF (p=0.56 for the USA, p=0.47 for Eng

274 ystis infections in transplantation units in France was evaluated through a retrospective survey.

275 In late 2013, France was one of the first countries to recommend initi

276 Colorex Strep A agar (CHROMagar, Paris, France) was evaluated with PhenoMATRIX chromogenic detec

277 patients from University Hospitals of Lyon, France, was used to calculate the endovascular distances

278 air quality measurement data from the UK and France, we demonstrate that road traffic exhaust has a f

279 In a prospective multicenter study in France, we evaluated GBS colonization in mother-baby pai

280 are estimated to amount to 12500 per year in France, we herein decided to compare the empirical clini

281 sylvatica L.) On Mont Ventoux, South-Eastern France, we located beech forest refugia at the time of t

282 nts with HBV- or HCV-associated cirrhosis in France, we validated the Baveno VI guidelines on screeni

283 ed, 32%-41% of the administrative regions of France were experiencing an epidemic, while the others w

284 ated with CRS/HIPEC between 2009 and 2018 in France were identified through a national medical databa

285 with reconstruction between 2010 and 2012 in France were included (n = 3286).

286 A total of 360 patients from 10 hospitals in France were included in the study.

287 re also tested in a quarantine laboratory in France where they were exposed to a French OsHV-1 microv

288 nducted in the Gironde estuary (southwestern France) where PFASs were ubiquitously detected albeit at

289 ittle intergenerational coresidence, such as France, whereas confining younger age groups can have a

290 the Paleolithic site at Le Rozel (Normandy, France), which represent the largest known Neandertal ic

291 be severely and negatively affected (Berce, France), while populations at the contemporary northern

292 nriched in a highly industrialized region in France with a cluster of sporadic PSP cases.

293 er Paris Area, the most populated regions in France with about 12 million inhabitants.

294 22 patients from three different centers in France with stages 2b and 3 COVID-19-associated pneumoni

295 UK, Germany, Finland, Australia, Sweden, and France), with biomarkers sampled between 1970 and 2010.

296 2015, to July 14, 2016, on the west coast of France, with GPs in 801 practices participating and invo

297 CO12 CirVir cohort, treated at 35 centers in France, with HCV or HBV infection and biopsy-proven cirr

298 d double-blind sequential trial conducted in France, with interim analyses planned every 50 patients.

299 ngle-group, phase 2 trial at 28 hospitals in France, with patients recruited from 17 hospitals.

300 e (UHI) Mediterranee Infection of Marseille, France, with the support of recent or representative stu